Expertise in
28
conditions

Dr. Irl B. Greenwell

Hematology | Oncology
Charleston Hematology Oncology Associates PA
2085 Henry Tecklenburg Dr Fl 2, 
Charleston, SC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
28
conditions
Charleston Hematology Oncology Associates PA
2085 Henry Tecklenburg Dr Fl 2, 
Charleston, SC 

Overview

Irl Greenwell is a Hematologist and an Oncologist practicing medicine in Charleston, South Carolina.

Dr. Greenwell is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Reticulohistiocytoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 16 peer reviewed articles and participating in 6 clinical trials. Dr. Greenwell is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in SC

Hospital Affiliations

Roper St Francis Hospital-Berkeley Inc
Roper Hospital
Musc Medical Center
Mount Pleasant Hospital
Bon Secours-St Francis Xavier Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Charleston Hematology Oncology Associates PA
2085 Henry Tecklenburg Dr Fl 2, Charleston, SC 29414

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas
A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas
Enrollment Status: Recruiting
Publish Date: September 02, 2026
Intervention Type: Drug
Study Drugs: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Etoposide, Duvelisib, Oral Azacitidine
Study Phase: Phase 2
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma
A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: July 24, 2026
Intervention Type: Drug
Study Drugs: Palbociclib, Ibrutinib
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2026
Intervention Type: Drug, Other
Study Drugs: Brentuximab vedotin, Rituximab, Lenalidomide
Study Phase: Phase 3
A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
Enrollment Status: Terminated
Publish Date: February 04, 2025
Intervention Type: Other, Biological
Study Drug: AB-205
Study Phase: Phase 3
A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)
A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)
Enrollment Status: Terminated
Publish Date: October 13, 2023
Intervention Type: Drug
Study Drug: Brentuximab
Study Phase: Phase 2
View 5 Less Clinical Trials

16 Total Publications

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.
Journal: Blood cancer journal
Published: December 12, 2025
Similar Doctors
Expertise in
37
conditions
Dr. Robert K. Stuart
Hematology | Oncology
Expertise in
37
conditions
Dr. Robert K. Stuart
Hematology | Oncology
Referral may be required

MUSC University Hospital

171 Ashley Ave, 
Charleston, SC 
 (5.7 miles away)
843-792-1414
Languages Spoken:
English
See accepted insurances

Robert Stuart is a Hematologist and an Oncologist practicing medicine in Charleston, South Carolina. Dr. Stuart is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
69
conditions
Dr. David M. Ellison
Hematology | Oncology
Expertise in
69
conditions
Dr. David M. Ellison
Hematology | Oncology
Referral may be required

Charleston Hematology Oncology Associates PA

2085 Henry Tecklenburg Dr Fl 2, 
Charleston, SC 
 (0.1 miles away)
843-577-6957
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Ellison is a Hematologist and an Oncologist practicing medicine in Charleston, South Carolina. Dr. Ellison is highly rated in 69 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Richter Syndrome, Chronic Lymphocytic Leukemia (CLL), Chromophobe Renal Cell Carcinoma, and Gastrostomy. Dr. Ellison is currently accepting new patients.

Expertise in
29
conditions
Dr. Gene B. Saylors
Hematology | Oncology
Expertise in
29
conditions
Dr. Gene B. Saylors
Hematology | Oncology
Referral may be required

Bon Secours St Francis Xavier Hospital Inc.

2910 Tricom St, 
North Charleston, SC 
 (11.5 miles away)
843-572-9211
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Gene Saylors is a Hematologist and an Oncologist practicing medicine in North Charleston, South Carolina. Dr. Saylors is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Colorectal Cancer, Pleuropulmonary Blastoma, Bone Marrow Aspiration, and Pancreatectomy. Dr. Saylors is currently accepting new patients.

Frequently Asked Questions about Dr. Irl B. Greenwell

How do I make an appointment with Dr. Irl B. Greenwell?

You can book an appointment with Dr. Irl B. Greenwell by calling their office at 843-577-6957. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Irl B. Greenwell a top-rated expert for Mantle Cell Lymphoma (MCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Irl B. Greenwell is classified as an Distinguished expert for Mantle Cell Lymphoma (MCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Irl B. Greenwell specialize in?

While Dr. Irl B. Greenwell is a Hematology, they have specific expertise in Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), and Reticulohistiocytoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Irl B. Greenwell participate in research or clinical trials?

Yes. Dr. Irl B. Greenwell has published 16 articles and abstracts on conditions like Mantle Cell Lymphoma (MCL). You can view a list of Dr. Irl B. Greenwell's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Irl B. Greenwell accept my insurance?

Dr. Irl B. Greenwell accepts most major insurance plans, including Absolute Total Care South Carolina and Aetna. We recommend calling the office directly at 843-577-6957 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Greenwell's expertise for a condition
ConditionClose
    View All 13 Distinguished Conditions
    View All 15 Advanced Conditions
    View All 36 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile